Abstract: An acrylic copolymer of ethyl acrylate and methacrylic acid wherein the weight ratio of ethyl acrylate to methacrylic acid is in a range between 75:25 and 95:5, containing therein a residual monomer content of 50 ppm or less, but substantially no surfactants, and which is useful as agents for protecting the skin and manufactured from the following essential components:a. an acrylic copolymer of ethyl acrylate and methacrylic acid wherein the weight ratio of ethyl acrylate to methacrylic acid is in a range between 75:25 and 95:5, containing therein residual monomers in an amount of 50 ppm or less, but substantially no surfactants--approximately 2 to 10%;b. cellulose derivative--approximately 0.2 to 2%; andc. a necessary amount of an aqueous alcohol to make the whole 100%.

Abstract: An acrylic copolymer of ethyl acrylate and methacrylic acid wherein the weight ratio of ethyl acrylate to methacrylic acid is in a range between 75:25 and 95:5, containing therein a residual monomer content of 50 ppm or less, but substantially no surfactants, and which is useful as agents for protecting the skin and manufactured from the following essential components:a. an acrylic copolymer of ethyl acrylate and methacrylic acid wherein the weight ratio of ethyl acrylate to methacrylic acid is in a range between 75:25 and 95:5, containing therein the residual monomers in an amount of 50 ppm or less, but substantially no surfactants . . . approximately 2 to 10%;b. cellulose derivative . . . approximately 0.2 to 2%; andc. a necessary amount of an aqueous alcohol to make the whole 100%.

Abstract: This invention relates to pharmaceutical compositions for the treatment of skin diseases which comprises as an active ingredient vitamin A esters of .alpha.-tocopherol.

Abstract: An improved process for the preparation of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and acid addition salts thereof, which are useful as a medicine. This process comprises effecting reaction between 4,5,6,7-tetrahydrothieno[3,2-c]pyridine and 2-chlorobenzyl halide in the presence of a phase transfer catalyst.

Abstract: New processes for preparing cholesta-1,5,7-trien-3-ol which is a key intermediate in the synthesis of 1.alpha.-hydroxyvitamin D.sub.3. The processes utilize the steps of reacting cholesta-1,4,6-trien-3-one with isopropenyl acetate in the presence of an acid catalyst followed by reduction of the resultant cholesta-1,3,5,7-tetraen-3-yl-acetate.

Abstract: A stabilized pharmaceutical composition containing 4-(3-tert.-butylamino-2-hydroxy)propoxy-2-methylisocarbostyril or an acid addition salt thereof as the active ingredient is now provided, in which the active ingredient compound is stabilized by addition of at least one of stabilizing agents selected from magnesium silicate, magnesium oxide, hydrotalcite and sodium hydrogen carbonate.

Abstract: An improved process for preparing 4-(4-biphenylyl)-4-oxo-butanoic acid which is useful as anti-inflammatory and analgesic agents. The process comprises reacting biphenyl with succinic anhydride in chlorobenzene in the presence of anhydrous aluminum chloride. No 4-(4-chlorophenyl)-4-oxo-butanoic acid is produced as by-product.

Abstract: A soft capsule containing as active ingredient .gamma.-oryzanol alone or oryzanol in combination with riboflavin butyrate is described. The shelf life of this composition is increased without precipitation of the ingredients thereof.

Abstract: L-carnitine and salts thereof are resolved from DL-carnitine by the use as a resolving agent of dibenzoyl-L(+)tartaric acid. L-carnitine is known as vitamin B.sub.T and is useful as a medicine.